The D’Or Institute for Research and Education (IDOR) is an organization located in the greater Rio de Janeiro area of Brazil. It is led by its founder Jorge Moll, Ph.D., who is the president-director and has a seat on this organization’s governing board. Their Cognitive Neuroscience is led by him as its education and research head. Additionally, he heads its Neuroinformatics Workgroup.
Jorge Moll was given the Research Fellow NIH award which lasted from 2004 to 2007. As of 2008 he is an affiliate member of the Brazilian Academy of Sciences. The International Neuroethics Society elected him to their governing board for two years, 2012 and 2013. He was also given a Visiting Scholar Award by Stanford University’s Stanford Neuroscience Institute in 2015.
In December 2017, Jorge Moll was interviewed by interview.net. He said that growing up he wanted to help people who had mental conditions which prevented them from fully enjoying life. He says he attended the Federal University of Rio de Janiero in order to start working on this dream. After earning his MD in neuroscience there he then graduated from Sao Paulo University with his Ph.D. in experimental pathophysiology.
The reason Jorge Moll established the D’Or Institute for Research and Education was to have one of the world’s top education research, and healthcare organizations in Brazil. He says his workdays is spent meeting with other people which include his organization’s students, researchers, scientists, and other entrepreneurs in the field of healthcare. Jorge Moll likes to collaborate with others and he says that it is vital to have a free exchange of information with others.
As someone very productive in his field, Jorge Moll says that he believes he maintains this by being transparent and open with others. He also credits being skillful at what he does. What he doesn’t think is very productive is that academia and the healthcare industry alike are actually hindering more scientific research and innovation being performed. He says that the designated career pathways and the healthcare field publications are too confining. He says these do not aspire to address the big challenges that this industry faces.